Semaglutide 1 mg

DRUG2 trials

Sponsors

Novo Nordisk A/S, Halia Therapeutics, Inc.

Conditions

Diabetes Mellitus, Type 2Obesity

Phase 2

A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM

WithdrawnNCT07172867

Halia Therapeutics, Inc.Diabetes Mellitus, Type 2, Obesity

Start: 2026-01-06End: 2026-01-23Updated: 2026-02-25

Phase 3

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)

CompletedNCT05259033

Novo Nordisk A/SDiabetes Mellitus, Type 2

Start: 2022-04-11End: 2024-01-16Updated: 2026-06-12

Related Papers

Efficacy and Hypoglycaemia Outcomes With Once‐Weekly <scp>IcoSema</scp> Versus Comparators in Individuals With Type 2 Diabetes by Kidney and Liver Function: A <i>Post Hoc</i> Analysis of the <scp>COMBINE</scp> 1–3 Trials

Diabetes Obesity and Metabolism2026-08-05

Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial.

2025-01-179 citations

Pharmacokinetic Properties of a Once-Weekly Fixed-Ratio Combination of Insulin Icodec and Semaglutide Compared with Separate Administration of Each Component in Individuals with Type 2 Diabetes Mellitus

Clinical Drug Investigation2024-11-019 citations